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ABSTRACT
The hypothesis tested in the epitope stability study is
that apo B
bound to a synthetic core of iodipamide ethyl ester (IDE) particles retain
stability, as detected by immunoreactivity of apo B
epitopes with two
monoclonal antibodies. The mAB 3.01 binds to the carboxy terminal end
of apo B-1 00. The mAB T4 binds to the T4 peptide fragment at the amino
terminal end of both apo B-1 00 and apo B-48. Stability of LDL-coated
IDE was evaluated over 40 days when stored at -20C, 4C and 25C.
Stability of reconstituted lyophilized IDE was evaluated over 42 days,
starting with particles that had been lyophilized for 14
days. For the
nonlyophilized LDL-coated IDE, lower temperatures (-20C and 4C)
appear to be more effective in slowing down degradation of apo B, as the
epitope immunoreactivity detected by the mABs was greater for these
temperatures than for 25C. Reconstituted lyophilized LDL-coated IDE
particles are effective in stabilizing apo B antigenic sites for at least 28
days. Interpretation of the results of the study must include a
consideration of the length of time LDL was stored at 4C before being
bound to IDE particles (13 days) and the length of time the LDL-coated
IDE was stored at 4C before lyophilization (14 days, or a total age of 27
days for LDL in vitro). This suggests that a future study of apo B epitope
stability utilizing LDL-coated IDE should use fresher LDL (apo B) for
coating IDE, followed by immediate lyophilization.
INTRODUCTION
Arteriosclerosis involves thickening, induration, hardening and loss of
elasticity of the arterial wall. Atherosclerosis is the most common form of
arteriosclerosis and is a condition in which atheromas, or areas of lipid
material, macrophages and connective tissue accumulate within the
intimal layers of blood vessels. Large atheromas can cause arterial
occlusion and when occlusion occurs in coronary arteries, heart attacks
occur.
Apolipoprotein B-1 00 is present in atherosclerotic plaques, within
foam cells and in the connective tissue associated with plaque (1,2).
Apo B-1 00 comprises 98% of the protein associated with low density
lipoprotein (LDL), 50-70% of the protein in intermediate density
lipoprotein (IDL), and 37% of the protein associated with very low
density lipoprotein (VLDL) (3). Apo B-1 00 is very large, with a
molecular weight of 550,000 Da. There is one apo B molecule per LDL
molecule. The ability to quantitate apo B accurately and easily has
become more important as researchers have demonstrated that
measurement of apo B is a more effective evaluator of risk and predictor
of cardiovascular disease than the more commonly used risk factors LDL
and high density lipoprotein (HDL) cholesterol. DeBacker et al. (4) found
that an apo B/apo A-l ratio was the best discriminator between a group of
70 males who had experienced myocardial infarction and a control group
of 70 healthy males. Noma et al. (5) found significant increases in LDL
cholesterol/HDL cholesterol, apo B/apo A-l and apo B/apo A-ll in patients
with coronary artery disease as compared to those without coronary
artery disease. Sniderman et al. (6) concluded, that although the risk
factors, cholesterol, triglyceride and LDL cholesterol were significantly
higher in 59 patients with coronary artery disease, when compared with
31 noncoronary patients, apo B concentration gave the best
differentiation between the two groups. Apo B was also elevated in a
subgroup of coronary
disease patients who had normal LDL
cholesterol
levels and this subgroup and others like
them have a condition known as
hyperapobetalipoproteinemia. Kukita et al. (7) also found that apos A-1
and B were better discriminators of coronary artery
disease patients
compared with healthy control subjects
than were cholesterol and
triglyceride levels alone.
Triacylglycerols, cholesterol and other dietary lipids are assembled
into chylomicrons in the intestinal mucosa with one molecule
of
apolipoprotein B-48, which is a required protein component (8). Apo
B-
48, which is produced only in the intestines of humans, is
identical to
48% of apo B-1 00, starting at the amino terminal end of the larger
molecule. After chylomicrons are secreted from enterocytes, they travel
through the lymphatic circulation to the thoracic duct and enter the
bloodstream. Chylomicrons entering the capillary endothelium of
skeletal muscle and adipose tissue undergo hydrolysis by lipoprotein
lipase and lose 80-90% of their triglyceride. The remaining
"cholesterol-
rich"
chylomicron remnants are transported to the liver and are taken up.
Hepatic cholesterol can be stored as cholesterol esters or can be used
for bile acid or lipoprotein synthesis.
In the liver, apo B-1 00 is necessary for the formation of VLDL. VLDL
is secreted from the liver into the portal vein. Like chylomicrons, the
triglyceride-rich core of VLDL is hydrolyzed by lipoprotein lipase within
the capillary endothelial bed. As the VLDL core is reduced, it is thought
that apo B-1 00 changes conformation and now can serve as a ligand for
uptake by hepatic receptors (apo B,E receptors). In humans, about 50%
VLDL remains in the circulation and is metabolized to LDL, which has a
lifespan of 3 days in plasma. Ultimately, about 80% of circulating LDL is
removed by the LDL receptor (apo B,E receptor). About 20% of
circulating LDL is removed by adsorptive endocytosis when LDL plasma
concentration is high. Inside the cell, LDL enters the lysosome, where
the protein is degraded and cholesteryl ester is hydrolyzed to free
cholesterol which can be used for cell membrane biosynthesis or
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reesterified with the monounsaturated fatty acids oleate and palmitoleate
to cholesterol esters, catalyzed by the enzyme acyl CoA:cholesterol acyl
transferase (ACAT). Through reverse cholesterol transport, HDL carries
cholesterol from tissues through the bloodstream, where plasma
lecithin:cholesterol acyltransferase (LCAT) converts cholesterol into
cholesteryl esters which can then be transferred to other lipoproteins
such as LDL. Some of the transported cholesterol is removed and
excreted via the liver.
Apo B-1 00 can be damaged by mechanical shear, can be degraded
via proteolysis, and may be modified by oxidation. During delipidation of
LDL, covalent and noncovalent interactions favor apo B self-aggregation
(9). In an attempt to stabilize this macromolecular protein, apo B is
coated onto iodipamide ethyl ester (IDE) particles, after delipidation of
the natural LDL core with dimethyl sulfoxide and ethyl alcohol (10).
This study tests the stability of apo B-1 00 on IDE particles using the
variables of time (1 day, 5 days, 12 days, 26 days and 40 days at stated
temperatures) and temperature (-20C, 4C, 25C and lyophile stored at
4C). Two monoclonal antibodies (mABs) are used to test the stability of
apo B-100-coated IDE particles. The mAB 3.01 binds to an epitope at the
carboxyl terminal end of apoB-100. The mAB T4 binds to an epitope at
the amino terminal end of apo B. 125l-goat anti-mouse whole IgG, is used
to detect mAB 3.01 or mAB T4 bound to apo B epitopes. The radioactivity
of this antigen-antibody-antibody complex is then measured by gamma
counting. LDL-coated IDE particles not exposed to primary antibody
(3.01 and T4) serve as nonspecific binding controls for each time-
temperature assay of LDL-coated particles exposed to primary antibody
(3.01 and T4).
LDL-coated and uncoated lyophilized particles are included in the
fourth through seventh assays, corresponding to 14, 28, 42, and 56 days
as lyophile stored at
4
C, respectively. The particles were not lyophilized
until 14 days after they were produced. Until lyophilization, they were
stored at 4C.
Preliminary work is also described in this paper. It includes a
comparison of three types of Immulon microtiter wells to determine if
there is a difference in binding of human LDL (apo B-1 00), experiments
to establish the correct dilutions of LDL (apoB-100) and monoclonal
antibodies 3.01 and T4 to use for the time-temperature experiment, and a
trial run of various dilutions of LDL-coated IDE particles in microtiter wells
and in 12x75 mm polystyrene test tubes.
10
MATERIALS AND METHODS
Source of human LDL
Six to eight red top clot tubes were donated by various human
volunteers, who fasted for 12 hours so that there would not be a
significant chylomicron fraction to consider when the serum was
separated via ultracentrifugation. The blood was allowed to clot at 4C.
The tubes were spun for 10 minutes at 2800 rpm (1270 x gAv) in a Sorvall
RT6000B Refrigerated Centrifuge (DuPont Co., Wilmington, DE) at 25C
to yield 35 mis serum (#316), 17.5 mis (#318) and 20.0 mis (#321). The
salt density of serum (1.006 g/ml) was adjusted to 1.019 g/ml.by addition
of solid sodium bromide (NaBr) using the formula g of NaBr = ((V1 in
mls)(D2-D1))/(1-0.26D2), where V1 is serum in mis, D1 is starting
density, D2 is final density and the specific volume of NaBr is 0.26 ml/g
(11). After ultracentrifugation, the VLDL/IDL layer was removed and the
salt density of the remaining serum was adjusted to 1 .050. The adjusted
serum was transferred to 6 thick wall polycarbonate 16x76mm
ultracentrifuge tubes (Beckman Instruments, Inc., Palo Alto, CA), with
each tube containing approximately equal amounts of serum. The tubes
were placed in an 80 Ti fixed angle rotor, (Beckman Instruments, Inc.,
Palo Alto, CA) and spun at 50,000 rpm (175,000 x gAv) at 14C for 18
hours in a Beckman L8-70 ultracentrifuge (Beckman Instruments, Palo
Alto, CA). The supernatant LDL layer, which consists of approximately
98% apo B, was removed from the top layer and it appeared clear yellow,
as it contains lipid soluble vitamins including beta carotenes. The
sodium bromide, used to adjust the salt density, was removed from the
LDL layer by dialysis using a 6L dialysate of 0.15 M sodium chloride and
2.5 mM ethylenediaminetetraacetic acid (EDTA), pH 7.4. The LDL layer
was divided into 2 portions and dialyzed using a 50,000 molecular
weight cut-off membrane (Spectrum Medical Industries Spectra/Por
molecular porous membrane tubing). LDL was dialyzed at 4C
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overnight. This process was repeated twice, using fresh dialysate for
each overnight dialysis. The final dialysate did not contain EDTA, to
allow EDTA from the first two dialysis steps to diffuse from the LDL
present in the Spectra/Por membrane tubing. After the final dialysis, the
LDL from each batch (#316, 318 and 321) was removed with several
washes of the membrane tubing, filter sterilized using a 0.2 \i filter and
placed in sterile test tubes. After dialysis, #316 yielded 7.5 mis LDL,
#318 yielded 1.75 mis , and #321 yielded 4 mis LDL.
Quantitation of the protein content of LDL
The Markwell protein procedure (12) is used to quantitate LDL protein
because the method employs a detergent which optimizes assay of
lipoprotein apoproteins compared with the Lowry method, from which it is
a modification. A 1.0 mg/ml bovine serum albumin stock standard was
diluted 1:10 with double distilled water to obtain a concentration of 100
u.g/ml BSA stock standard. The dilution stock standard was used to make
working standards used in the Markwell protein procedure.
WORKING STANDARD STOCK STANDARD 0.9% SALINE








Three dilutions of each LDL preparation were made, using 10 jj.l plus
990 ul saline, 25 fxl plus 975 ul saline, and 50 ul plus 950 ul saline, in
order to have the sample with unknown protein content within the range
of standards.
12
In addition to the BSA standards, reagents used in the Markwell
protein determination are Reagent A and Reagent B. Alkaline carbonate
(Reagent A) consists of 20 g sodium carbonate (Na2C03), 4 g sodium
hydroxide (NaOH), 1.6 g sodium potassium tartrate, and 10 g sodium
dodecylsulfate (SDS) made up to a 1 liter solution with distilled water.
Copper sulfate (Reagent B) is 40 g CuS04/5H20 made up to a 1 liter
solution with distilled water. One hundred parts (70 mis) of Reagent A
(stable) were combined with 1 part (0.7 ml) Reagent B (stable) to make
Reagent C (unstable). Six test tubes were labelled for duplicate testing
of each of the 3 dilutions of LDL. Six tubes were labelled for each of the
BSA standard dilutions, and a tube was labelled for the blank (no protein
present). Three mis of Reagent C were added to each tube containing
1.0 ml of working standard, LDL dilution, or saline. This mixture was
incubated at room temperature for at least 10 minutes. Folin Ciocalteu
Reagent was freshly diluted 1:2 on the assay day using 1 part distilled
water and 1 part concentrated (2N) Folin and Ciocalteu Phenol Reagent
(100 g sodium tungstate, 25 g sodium molybdate, 700 mis H20, 50 mis
85% phosphoric acid and 100 mis concentrated HCI, 150 g lithium
sulfate and 50 mis H20 diluted to 1 liter with H20). This reagent was
purchased from Sigma Chemical Co., St. Louis, MO. An amount of 0.3
ml Folin reagent was added to each tube. The tubes were vortexed
immediately after the Folin reagent was added to insure maximum color
development in the presence of protein. Folin reagent is most reactive at
pH 10, but for a only short time. The tubes were incubated at room
temperature for 45 minutes and the absorbance of blue color developed
in each tube was read at 660 nm on a Stasar II Gilford
Spectrophotometer. To obtain a standard curve, absorbance readings
for standards (y-axis) were plotted against concentrations of standards
(x-axis). The protein content of LDL was determined from an average
reading of the three dilutions obtained
from the standard curve and











#316 35.0 mis 7.50 mis
3.70 mg/ml 79 mg/dl
#318 17.5 mis 1.75 mis
13.53 mg/ml 151 mg/dl
#321 20.0 mis 4.00 mis 4.59
mg/ml 93 mg/dl
Storage of LDL
A stock solution of 0.25M EDTA, pH7.4, was added to
the LDL in the
ratio of 1:100 to yield a final concentration of
2.5mM EDTA. The LDL
was then filter sterilized using a 0.2 (im Acrodisc
filter and divided into




Two mABs were used in these experiments. The mAB 3.01 against
human LDL at the carboxy terminal of apo B1-00 only, was prepared in
the laboratory of Dr. Charles E. Sparks, Department of Pathology and
Laboratory Medicine, University of Rochester, School of Medicine and
Dentistry. The method used was the standard technique using a mouse
spleen cells fusion to myeloma cells. Culture supernatants from
microtiter wells containing growing fused cells were tested for antibody
specific for the human LDL using a two-antibody solid phase
radioimmunoassay. Cells producing the specific antibody were used to
produce ascites fluid from pristane-primed BALB-c/ByJ mice (13). The
IgG was purified from the ascites fluid with a two-step procedure, using
caprylic acid to precipitate albumin and other serum proteins, then
ammonium sulfate was used to selectively precipitate the IgG fraction
from the supernatant (14). The mAB 3.01 was found to be composed of
two mABs of the lgG1 and lgG2b isotype by a double immunodiffusion
technique (15). This mAB was aliquoted into 25 \i\ samples and stored
at -20C.
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The second mAB was obtained commercially. It is against human low
density lipoprotein apo B, clone 5F8, immunoglobulin type lgG1 (MON
5025, MONOSCAN, AM Uden, the Netherlands). The mAB is specific for
an epitope on fragment T4, the amino terminal thrombolytic peptide of
both human apo B-1 00 and B-48. It was divided into 25 ul samples and
stored at -20C.
Polyclonal antibody (Second antibody)
The radiolabelled antibody used in the preliminary work for the
time-
temperature experiment was 125l-sheep anti- mouse whole antibody,
purchased from Amersham Corp. (Arlington Heights, ILL). Second
antibody used in the time-temperature study was 125l-goat anti-mouse
whole IgG, purchased from E.I. du Pont de Nemours & Co., Inc.
(Wilmington, DE).
Crystal and Aggregate Test
Iodipamide ethyl ester (IDE) particles may form crystals and/or
aggregates. Each IDE batch prepared is checked for the presence of
crystals and/or aggregates. The particle suspension is diluted to 3
mg/ml. A drop of particle suspension is placed on a microscope slide,
coverslipped and examined under 400x magnification. Five fields are
examined, each a 4x4 grid of 25x25 u.m squares on the reticle. Crystals
and aggregates are counted in each of four size ranges (>25 u_ti, 10-25
p.m, 5-10 |im and <5 (im). The particle suspension must pass
specifications for all four size ranges.
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Diameter Determination
A Coulter N4 SD Sub-Micron Particle Analyzer (Coulter Diagnostics,
Hialeah, FL) is used to determine particle size. The
particle suspension
(100 j_lI) was diluted with filtered water
(3.0 mis) in a cuvette, mixed, and
placed into the Coulter N4. Particles in solution move randomly, with
motion caused by thermal agitation. Particles in Brownian
motion are
illuminated by a 4 mW helium-neon laser. Light scattered by these
particles is detected by a photomultiplier. Photon correlation
spectroscopy is based on measuring scattered
light fluctuations.
Particles are sized by characterization of the exact time scale of the
random intensity fluctuations caused by changing patterns of diffusing
Brownian particles (16).
Density (XES) Analysis
A Canberra Series 35 Multichannel analyzer (Canberra Industries,
Inc., Meriden, CONN) for x-ray excitation or fluorescent excitation
analysis measures concentrations of nonradioactive iodine in vitro to
determine IDE particle density. When a photon from the excitation
source with higher energy than the binding of the electrons closest to the
nucleus and with the lowest energy level, interacts with an atom, one of
these K-shell electrons may be ejected. As an electron from a higher
energy level (L or M) fills the empty K-shell spot, the atom emits photons
of two different energies. (K-alpha and K-beta). Each element has a
unique K-alpha and K-beta. The number of characteristic photons
produced by the interaction of the excitation source (Americium-241) with
the iodine K-shell electrons is directly related to the concentration of
iodine in the unknown sample. Area under a standard curve generated
by the analyzer is used for calculation of density. Results are given as
mg/ml (17).
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Packard Multi-Prias 4 Gamma Counter (Packard Instrument Co.,
Downers Grove, ILL)
125l emits gamma rays which travel through a sodium iodide crystal and
interact with the crystal's electrons to produce scintillations of light. The
amount of light produced by each gamma ray is proportional to the
amount of energy lost by the gamma ray inside the crystal. Photons
produced in the crystal after exposure to gamma rays go to a
photocathode inside a photomultiplier tube. The photocathode emits an
electron when a photon is absorbed. Electrons strike the surface of a
dynode (positively charged electrode), where 2 electrons are ejected.
These electrons multiply as they are accelerated to several successively
more positive dynodes. Electrons collect at the anode as an electrical
pulse measured in volts. The counting efficiency of the Multi-Prias 4 for
125l is about 70%. (18)
Preparation of Incubation/Wash/Dilution Buffer (1 L)
0.01 M phosphate buffer/0.15 M sodium chloride, pH 7.4
1%, w/v, bovine serum albumin
1%, w/v, nonfat dry milk
0.01%, w/v, sodium azide
Distilled water to bring total volume to 1 L
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PRELIMINARY STUDIES
EXPERIMENT 1: Comparison of Immulon 2, 3 and 4 Microtiter
Wells
The purpose of this experiment is threefold:
1. to compare the effectiveness of Immulon 2, 3 and 4 microtiter wells to
bind human LDL;
2. to compare the competitive binding of human LDL, where both human
LDL coating the well and and human LDL in solution are varied;
3. to compare the binding characteristics of mAB 3.01, which binds to an
epitope at the carboxyl terminal of apolipoprotein B versus binding of
mAB T4, which binds to an epitope at the amino terminal end of
apolipoprotein B.
Material and Methods
Reagents for Coating Immulon Microtiter Wells
Carbonate/bicarbonate buffer (pH 9.6): 0.80 g Na2C03 (sodium
bicarbonate), 0.10 g NaN3 (sodium azide), and 1.47 g NaHC03 (sodium
bicarbonate) diluted to 500 mis with double distilled water. This reagent
is stored at 4C.
1% BSA/PBS: 50 mis sterile phosphate buffered saline and 16.7 mis
30% bovine albumin, diluted to 500 mis with double distilled water. This
reagent is stored at 4C.
Three different concentrations of #316 LDL were prepared. First, a
dilute stock solution of 370 ug/ml #316 LDL was made. Then, 7.5, 10.0
and 15.0 ^ig/ml solutions of LDL were prepared from the dilute stock
solution plus carbonate/bicarbonate buffer. One plate each of Immulon
2, 3 and 4 Removawell strips (Dynatech Laboratories, Inc., Alexandria,
VA) were used. Rows A and B of each plate were coated with 0.1 ml 15
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ug/ml #316 LDL, rows C and D were coated with 0.1 ml 10 ug/ml #316
LDL, rows E and F were coated with 0.1 ml 7.5 ug/ml #316 LDL, and
rows G and H (controls) were coated with 0.1 ml carbonate/bicarbonate
buffer. The three plates were each placed on top of a water-moistened
paper towel inside a plastic ziplock bag and incubated at 4C overnight.
The next morning, the plates were drained, blotted on a paper towel, and
washed two times with 1% bovine serum albumin in phosphate buffered
saline (BSA/PBS). The three plates were post-coated at room
temperature for 4 hours with 1% BSA/PBS filling each well to block any
remaining protein-binding active sites. Next, the plates were then
washed three times each with 1% BSA/PBS. Standard solutions of #316
LDL were prepared as follows.
#316 LDL STOCK STD #316 LDL 1% BSA/PBS
10 p.g/ml 10 jj.Is 3.960 mis
STANDARD #316 LDL STOCK STD 1% BSA/PBS
0.25 ug/ml 0.25 mis 9.75 mis
0.50 u.g/ml 0.50 mis 9.50 mis
1.50pg/ml 1.50 mis 8.5 mis
Dilutions of 1:15,000 for mAB 3.01 and 1:1000 for mAB T4 were also
prepared. To wells 1, 2 and 3 of each plate, 0.1 ml 1% BSA/PBS
(control) was added; to wells 4, 5 and 6, 0.1 ml 0.25 |ig/ml #316 LDLwas
added; to wells 7, 8 and 9, 0.1 ml 0.50 (ig/ml #316 LDL was added.
Wells 10, 11 and 12 were inoculated with 0.1 ml 1.50 ug/ml #316 LDL.
Immediately following this step, 0.1 ml 3.01 (1:15,000) was added to rows
A, C, E and G. An amount of 0.1 ml T4 (1:1000) was added to rows B, D,
F and H. The plates were incubated at 4C overnight, each humidified
on top of a water-moistened
paper towel inside a plastic ziplock bag.
The next morning, the plates were washed three times in 1% BSA/PBS.
.25|.sheep
anti-mouse whole antibody was diluted in 1% BSA/PBS so
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that there would be approximately 50,000 cpm per well when
0.1 ml of
the diluted second antibody was added per well. Therefore,
approximately 25 u.Ci second antibody would be
needed per plate. A
total of 75 |ils second antibody was diluted to 30 mis 1% BSA/PBS for
three plates. An amount of 0.1 ml of this dilution was added to each well
of the three plates. Each plate was placed over a water-moistened paper
towel and put into a plastic ziplock bag. The plates were stored at 4C
overnight. The next morning, the three plates were drained and washed
three times with 1% BSA/PBS. The wells were broken off each strip one
by one and placed into 12x75 mm polystyrene test tubes. The tubes
were counted for two minutes each on a Packard Multi-Prias 4 Gamma
Counter (Packard Instrument Co., Downers Grove, ILL). The triplicate
sets of counts were averaged. For each Immulon type (2,3 and 4), the
cpm (y-axis) for three different dilutions of #316 LDL (7.5, 10 and 15
Ug/ml) were plotted against (ig/ml #316 LDL (x-axis). Four different
concentrations of #316 LDL were used to coat each plate: 0.0, 7.5, 10.0
and 15.0 ug/ml.
Results and Discussion
Figures 1 and 2 contain graphs of cpm of radiolabeled whole IgG
antibody attached to mAB 3.01 or mAB T4 bound to LDL (apo B-1 00)-
coated microtiter wells as a function of increasing concentrations of LDL
added to the LDL-coated microtiter wells. For all three Immulon plastics
tested, there is an inverse relationship between the amount of LDL (apo
B-1 00) added in solution and the antigen (apoB-100)-antibody (mAB
3.01 or T4)-antibody (^-labelled) complexes in the bottom of the wells.
As more LDL (apo B-1 00) is added, more of the ^-labelled antibody
binds to the LDL (apo B-100)-mAB complexes which are washed away
before the wells are counted. Therefore, the cpm decrease.
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Legend for Figure 1
Plot of data from Experiment 1 using mAB 3.01 (1:15,000) to detect to
apo B epitopes. For each of 3 Immulon plastics, CPM for 3
concentrations of LDL (apo B) in u.g/ml coating Immulon microtiter wells
are plotted as a function of 4 concentrations of LDL (apo B) in solution
(|ig/ml). LDL (apo B) coating the wells compete with LDL (apo B) in
solution. As the concentration of LDL in solution increases, more mAB
binds to LDL in solution and less binds to the LDL bound to the wells,
resulting in decreased counts.
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Legend for Figure 2
Plot of data from Experiment 1 using mAB T4 (1:1000) to detect to apo B
epitopes. For each of 3 Immulon plastics, CPM for 3 concentrations of
LDL (apo B) in ug/ml coating Immulon microtiter wells are plotted as a
function of 4 concentrations of LDL (apo B) in solution (u.g/ml). LDL (apo
B) coating the wells compete with LDL (apo B) in solution. As the
concentration of LDL in solution increases, more mAB binds to LDL in




Any observed differences among LDL concentration curves for
Immulon plastics 2, 3 and 4, as seen in Figures 1 and 2, are interpreted
to be very slight. Therefore, it was decided to continue to use Immulon 2
microtiter wells for work with human apo B-1 00.
EXPERIMENT 2
The purpose of this experiment is to test monoclonal antibody 3.01
(1:10,000) and T4 (1:2000) binding to human LDL and to establish the
optimal mAB dilution to use to develop a useful standard curve from
concentrations of first antibody ranging from 0 fig/ml to 2.5 jig/ml. The
concentration of T4 in this experiment was changed from 1:1000
(Experiment 1) to 1:2000 in an attempt to shift the curve to the left to
eliminate the part of the curve which does not contribute to the workable
standard curve.
Materials and Methods
Only Immulon 2 Removawell strips were used for this experiment
because it was determined from Experiment 1 that there was little
meaningful difference in effectiveness of binding apo B-1 00 among the
Immulon types 2, 3 and 4. Ninety-six wells of Immulon 2 Removawell
strips were incubated at 4C overnight with 0.1 ml 15 |ig/ml #316 LDL in
carbonate/bicarbonate buffer in each well. The concentration of 15 u.g/ml
was chosen because it was determined from Experiment 1 that each
concentration of LDL tested (7.5 (il/ml, 10 |il/ml and 15 nl/ml) resulted in
approximately the same shape curve and that concentration has been
routinely used in the past. After overnight incubation, the plate was
washed two times with 1% BSA/PBS. The third wash was used to block
any remaining active protein-binding
sites on the wells for four hours at
room temperature.
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Preparation of LDL Standard Curve
A stock solution of 2.5 ug/ml #316 LDL was
prepared from a 10 pg/ml
#316 LDL (10 pi 3690 pis 1% BSA/PBS ) by diluting
2 mis of 10 ug/ml
#316 LDL with 6 mis 1% BSA/PBS. The
standard curve was prepared as
described in Table 1 .
Preparation of microtiter wells
After the #316 LDL standard curve was prepared and
the monoclonal
antibodies were diluted, the blocked plate was drained.
An amount of
0.1 ml of each standard concentration of #316 LDL was
added to two
sets of wells on the plate, three wells per standard
dilution. Then, 0.1 ml
of monoclonal antibody 3.01 (1:10,000) was added to one
set of wells
and monoclonal antibody T4 (1:2000) was added to the other set
of
triplicate wells. The plate was placed over a water-moistened paper
towel, then into a plastic ziplock bag. It was incubated overnight at 4C.
After incubation, the plate was washed three times with 1% BSA/PBS.
The second antibody, 125l-sheep anti-mouse whole IgG was diluted 25 pi
to 10 mis 1% BSA/PBS. An amount of 0.1 ml of the second antibody
dilution was added to each well. The plate incubated overnight at 4C in
a plastic ziplock bag. The following morning, the plate was washed three
times with 1% BSA/PBS. After the last wash, the wells were place one by
one into the bottom of 12x75 mm polystyrene tubes. The tubes were
counted for one minute each on a Packard Multi-Prias 4 Gamma
Counter. Cpm (y-axis) was plotted against concentration of LDL in pg/ml
(x-axis) for each of the two mABs (3.01 and T4).
Results and Discussion
A 1:10,000 dilution of monoclonal antibody 3.01 and a 1:2000 dilution
of T4 have approximately the same shape curve when concentrations of
LDL standards ranging from 0.5 pg/ml to 2.5 pg/ml are used as seen in
Figure 3.
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Table 1. Dilutions of LDL for standard curve
in Experiments 2, 3 and 4.
The LDL standard range is 0-2.5 pg/ml. The second column
lists mis of 2.5 pg/ml stock solution of LDL and the third column
lists mis of 1% BSA/PBS required to prepare the corresponding
standard in the first column.
LDL Standard
(pg/ml)































Legend for Figure 3
Plot of results for Experiment 2. When CPM of the 125l-labelled whole IgG
bound to 15 pg LDL (apo B)/ml coating the microtiter wells is plotted vs
pg LDL (apo B)/ml added in solution, a workable standard curve is
obtained for mABs 3.01 (1:10,000) and T4 (1:2000).
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Summary
A workable standard curve for LDL apo B-1 00 in the range of 0.5 to
2.5 pg/ml is obtained when first antibody dilutions are 1:10,000
for 3.01
and 1:2000 for T4.
EXPERIMENT 3
This experiment was designed to use the LDL coated particles as
solid phase standards in a microtiter competitive radioimmunoassay.
A range of concentrations of iodipamide ethyl ester (IDE) particles
coated with #318 LDL is simultaneously exposed to #316 LDL coating
the bottom of Immulon 2 wells and monoclonal antibody 3.01 (1:10,000)
or monoclonal antibody T4 (1:2000). The
125l-
sheep anti-mouse IgG
whole antibody was from the same source as used in Experiment 2. The
#316 LDL standard curve dilutions (Table 2) were set up as a control for
each monoclonal antibody tested. A triplicate set of blank wells,
consisting of wash solution only, was also included for each of the two
monoclonal antibodies tested.
Material and Methods
IDE particles (19) were prepared in Dr. Michael Violante's laboratory in
the Experimental Radiology Department at the University of Rochester.
1. Add 96 mis IDE solution to a 2000 ml beaker.
2. Add 125 mis absolute ethanol, using the same graduated cylinder as
for the IDE.
3. Add approximately 1 inch of acetone to the crystallizing dish and
adjust the temperature to -3C by adding small pieces of dry ice.
4. Using a 60 cc plastic slip-tip syringe, 19 g butterfly infusion set and
Harvard Apparatus infusion pump (Figure 4), begin infusion of 250
mis 1% polyvinyl pyrrolidone (PVP, pH 5) in 20 ml increments. Stir
beaker contents as fast as possible without splashing. Temperature
rises as PVP is added.
30
5. Using additional dry ice, adjust temperature to approximately -2C for
particle precipitation, which occurs after the first 114 mis 1% PVP is
infused.
6. Add dry ice as needed to maintain temperature at about 5C after
precipitation as the remainder of 1% PVP is added.
7. Immediately stabilize with 150 mis 1% PVP (pH 7.4).
8. Immediately add to the suspension 0.31 ml LDL (#318) stock solution
containing 5 mg/ml.
9. Adjust to 3 mg IDE/ml to evaluate a yellow suspension for aggregates
and crystals. Determine average particle size.
Washing IDE Particles
1. Pour the suspension into three 250 ml centrifuge bottles.
Centrifuge 3000 rpm (1381xgmax) for 60 minutes. Decant, save a 1 ml
sample for XES (density) analysis, measure volume, and discard
supernate.
2. For the first wash, add 125 mis 0.1% PVP (pH 7.4) to each bottle. Add
4.4 mis of a 20 mg/ml solution of casein (nonfat dry milk) to each
bottle to block any remaining active protein-binding sites on the IDE
particles. Resuspend particle plug in each bottle by vigorous manual
shaking. Centrifuge 3000 rpm (1381xgmax)for 45 minutes. Decant,
save 1 ml sample for XES analysis, measure volume, and discard
supernate.
3. For the second wash, add 125 mis 0.1% PVP (pH 7.4) to each bottle.
Resuspend particle plug with vigorous manual shaking. Centrifuge
3000 rpm (1381Xgmax) for 45 minutes. Decant, save 1 ml sample for
XES analysis, measure volume, and discard supernate.
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Legend for Figure 4
Equipment for IDE particle production includes a 60 cc syringe attached
to a Harvard apparatus infusion pump. A 19 g butterfly set connected to
the syringe is used to add 1% PVP (pH 5) to the IDE solution and
absolute ethanol in the beaker to precipitate IDE. The solution is
constantly stirred using a magnetic stirrer. A shallow pan of acetone and
dry ice is used to adjust the reaction temperature to -2C for particle
precipitation.
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4. For the third wash, resuspend with 0.1% PVP
(pH 7.4) while
combining 3 into 2 bottles for a
final volume of approximately 125 mis
per bottle.
Resuspend particle plug in each bottle by vigorously
shaking.
Centrifuge 3000 rpm (1381Xgmax) for 45 minutes. Decant, save 1 ml
sample for XES analysis, measure volume, and discard supernate.
5. For the fourth wash, resuspend with 0.1% PVP (pH 7.4) while
combining 2 bottles into 1 for a final volume of about
125 mis per
bottle. Resuspend particle plug with vigorous manual shaking.
Centrifuge 3000 rpm (1381xgmax)for 45 minutes. Decant, save 1 ml
sample for XES analysis, measure volume, and discard supernate.
6. For the fifth wash, 125 mis 0.1% PVP (pH 7.4).to the bottle.
Resuspend particle plug with vigorous manual shaking. Centrifuge
3000 rpm (1381Xgmax) for 45 minutes. Decant, save 1 ml sample for
XES analysis, measure volume, and discard supernate.
7. Add 45 mis 0.1% PVP (pH 7.4), using a graduated cylinder.
Resuspend particle plug by vigorously shaking.
8. Place approximately 1 ml of IDE suspension into a 2-ml vacutainer
tube. Store final particle suspension (about 50 mis) and final sample
(1 ml) at 4C for at least 4 hours before evaluating for density, particle
size, aggregates and crystals.
Particle Suspension Evaluation
1. Determine iodine (IDE) concentration using x-ray fluorescence
instrument and 50 pi samples in triplicate. Calculate batch recovery.
2. Adjust IDE concentration to 3 mg IDE/ml. Perform Aggregate and
Crystal test.
3. Determine average particle size using Coulter N4.
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Serial dilutions of LDL-coated particles
This standard curve was prepared as decsribed in Table 3 for each
mAB tested. A stock solution of 2.5 pg LDL-coated IDE/ml was prepared
using LDL (#318)-coated IDE particles.
Standard Curve Dilutions using LDL (#316)
LDL (#316) was diluted to obtain a concentration of 2.5 pl/ml. The
standard curve for LDL (#316) was prepared by using the dilutions listed
in Table 3.
Preparation of microtiter wells
Two 96-well Immulon 2 plates were coated with 0.1 ml of 15 pg/ml
LDL (#316), and were incubated at
4
C for 2 days. On the first day after
the plates were coated with LDL (#316), the LDL-coated IDE particles
were made and coated with LDL (#318). After settling overnight, the IDE
particles were measured for size. The two plates were blocked with 1%
BSA/PBS. For each plate, 0.1 ml each of all the standard curve
concentrations of LDL (#316) was introduced into each of 3 wells. Three
wells on each plate were also inoculated with 0.1 ml 1% PVP, the IDE
particle diluent. Both plates were also inoculated with 0.1 ml of each of
the LDL (#318)/IDE standard dilutions. An amount of 0.1 ml mAB 3.01
(1:10,000 dilution) was added to every well on one plate. An amount of
0.1 ml T4 (1:2000 dilution) was added to all wells of the second plate.
After overnight incubation at 4C, the plates were washed three times
with 1% BSA/PBS. The 125l-sheep anti-mouse whole IgG was diluted and
an amount of 0.1 ml of the diluted second antibody was added to all wells
after washing. The plates incubated overnight at 4C. The next morning,
the wells were washed three times in 1% BSA/PBS, they were broken off
into appropriately labelled 12x75 mm polystyrene tubes and counted on
a Multi-Prias 4 Gamma Counter for 10 minutes each. CPM were
averaged for each triplicate set and plotted on the y-axis against
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standard curve concentrations of LDL (#316) on the x-axis. A separate
graph was made for each of the two mABs.
Results and Discussion
Characterization of IDE and LDL-coated IDE particles
IDE precipitation was observed at 0.5C and after about 1 14 mis 1% PVP
infused. The end of infusion temperature was 6.5C. Temperature after
stabilization was 9C.
Crystal and Aggregate Test before LDL-coated IDE washed
Microscopic examination: All round, uniform, individual particles; very,
very small, no aggregates, an occasional small (about 5 p) and larger
(about 15 p) crystal mass.
Use 3 mg/ml. (5244 mg/621 ml = 8.4 mg/ml x (36 pl/100 pi) = 3 mg/ml)
Size: >25p >10p >5p >1p
Aggregate: max # allowed: <1 <2 <7 <27
PJD 31 -74a # counted: 0 0 0 0 Passes
Crystal: max # allowed: <1 <2 <5 <15
PJD 31 -74a # counted: 0 11 3 Passes
Crystal and Aggregate Test after LDL-coated IDE washed
Microscopic examination: All round, uniform, individual particles; very,
very small, no aggregates, an occasional small (about 5 p) and larger
(about 15p) crystal mass.
From density determination, an average density of 67 mg IDE/ml is
calculated.
Use 67 mg IDE/ml x 22pl/500pl to obtain the desired concentration of 3
mg IDE/ml for the crystal and aggregate test.
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Size: >25p >10p >5p >1p
Aggregate: max # allowed ; <1 <2 <7 <27
PJD 31 -76a # counted: 0 0 0 0 IDasses
Crystal: max # allowed: <1 <2 <5 <15
PJD 31 -76a # counted: 0 0 0 1 1Dasses
Diameter determinations
N4 Analysis: Before washing LDL-IDE After washing LDL-IDE
Unimodal Mean SD Mean SD
PJD 31 -74a. 1 268 70 PJD 31 -76a. 1 298 60
.2 267 52 .2 300 Narrow
.3 274 59 .3 303 66
.4 272 65 .4 303 59
AVG 270 nm 62 301 nm 62
Density determination
XES:lntegrate: I divided by 0.637 = IDEx volume IDE
217-245 mg/ml mg/ml ml mg
STD 80 92,313 79.1
STD 10 38,437 9.9
31 -76a. 1 66,213 43.2 67.8 53 3591
.2 65,585 42.4 66.5 53 3524
.3 65,728 42.5 66.8 53 3539
1) For 80 STD, calculate I using y = 0.003442X-squared + 0.8332 X
-
27.10; R=0.9991
2) For 10 STD, calculate I using y
= 0.9598X - 26.95; R=0.9961
Recovery: In: 5244 mg IDE
Out: 3551 mg IDE
3551/5244x100 = 67.7%
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NOTE: An error of +/- 2 mis in the estimate of the final
suspension volume
of 53 mis (a very real possibility) will
result in an error of
+/- 2.6% in the
recovery.
67.0 mg IDE/ml x 2 mis = 134 IDE/5244 mg
IDE x 100 = 2.6%
NOTE: IDE particles coated with #318 LDL were determined to be 301
nm +/- 62 nm, with an average concentration of 67.0 mg
IDE/ml solution
(6.7 trillion particles) or 2.495 pg/ml apolipoprotein
B. Final yield of
particles coated with #318 LDL was 53 mis.
Approximation of apo B on IDE particles coated with LDL
As determined by the Markwell protein procedure, there are 5 mg apo
B per ml. There are 1.55 mgs apo B present in 621 mis of solution used
to prepare the IDE particles. This is equivalent to 2.495 pg/ml apo B in
solution. Assuming all of the apo B has coated the IDE particles in a final
volume of 53 mis, then there are 29.2 pg apo B/ml. The standard curve
we prepared using LDL (#318)-coated IDE particles as a starting point
assumes 100% incorporation of LDL onto the IDE particles. The
standard curves for mABs 3.01 and T4 binding to LDL (apo B-1 00) alone
served as controls for this experiment. Their curves (Figure 5) were
similar to those obtained in Experiment 2. The LDL (apoB-100)-IDE
standard curve using mAB 3.01 appears to be flat (Figure 5). The counts
for this curve did not vary more than 1089 cpm between the lowest (0.1
pg/ml) and highest concentrations (2.5 pg/ml). The standard curve using
mAB T4 is also flat, with counts not varying more than 1343 cpm between
the lowest (0.1 pg/ml) and highest concentrations (2.5 pg/ml).
Summary
It appears that there is not sufficient LDL (apo B-1 00 ) which coats the
IDE particles to compete with the LDL bound to the microtiter wells for
mABs 3.01 or T4. For future work, the LDL concentration used to coat
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Legend for Figure 5
Plot of results of Experiment 3, where standard curves of LDL in solution
are compared to standard surves of LDL-coated IDE. CPM of
125l-
labelled whole IgG bound to mAB bound to 15 pg LDL (apo B)/ml coating
the microtiter well vs pg LDL (apo B)/ml added in solution to compete
with the bound LDL (apo B) for mAB. Results produce workable standard
curves when mABs 3.01 and T4 are used to detect LDL (apo B) epitopes
in a competitive radioimmunoassay. The LDL (apoB-100)-IDE standard
curve using mAB 3.01 appears to be flat. The counts for this curve did not
vary more than 1089 cpm between the lowest (0.1 pg/ml) and highest
concentrations (2.5 pg/ml). The standard curve using mAB T4 is also flat,
with counts not varying more than 1343 cpm between the lowest (0.1
pg/ml) and highest concentrations (2.5 pg/ml).
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IDE particles should be increased or the amount of LDL-coated IDE
present could be increased to determine if an LDL (apo B-100)-coated
IDE particle standard curve could be established. It was decided to try a
test tube assay.
EXPERIMENT 4
Since it was not possible to adapt a microtiter assay for LDL-coated
IDE particles, this experiment tests IDE particles coated with LDL (#318)
using a test tube assay, rather than microtiter wells. In this experiment,
IDE particle concentration remains constant and the mAB 3.01 and T4
concentrations vary to determine the optimal antibody dilution to use.
Materials and Methods
Coated IDE particles: Iodipamide ethyl ester particles coated with
LDL (#318)
mABs: 3.01 and T4
Second antibody: 125l-sheep anti-mouse whole IgG
Procedure
1. Dilute IDE particles (1:5) in incubation buffer, using a 50 ml centrifuge
tube.
(Three mis of particles were diluted with 15 mis incubation buffer.)
2. Pellet beads at 2800 rpm (1335xgmax) for 10 minutes. Discard
supernatant and resuspend in incubation buffer. Repeat this step.
3. Aliquot out washed beads into RIA tubes (12x75 mm polystyrene
tubes), 0.5 ml per tube. Label tubes 1 through 12 (for mAB 3.01) and
1 through 12 (for mAB T4).
4. Pellet beads in RIA tubes at 2800 rpm (1335Xgmax ) for 10 minutes.
5. Resuspend beads in the following dilutions of antibody in incubation
buffer.
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TUBE 1,2 0.5 ml of incubation buffer
TUBE 3,4 0.5 ml antibody diluted 1:100
TUBE 5,6 0.5 ml antibody diluted 1:200
TUBE 7,8 0.5 ml antibody diluted 1:500
TUBE 9,10 0.5 ml antibody diluted 1:1000
TUBE 11, 12.. .0.5 ml antibody diluted 1:5000
6. Incubate overnight at 4C.
7. Pellet all particles at 2800 rpm (1335xgmax) for 10 minutes.at 10C.
Remove the supernatant and repeat twice more.
8. Resuspend beads in 1.0 ml 125l-sheep anti-mouse whole IgG in
incubation buffer (75 pis 125l-sheep anti-mouse whole IgG in 30 mis
incubation buffer).
9. Incubate at 4C overnight.
10. Pellet beads and remove supernatant completely. Wash pellets three
times in 1.0 ml incubation buffer.
11. After last pelleting, resuspend beads in 0.25 ml incubation buffer.
Cap tubes and count for 10 minutes each on Packard Multi-Prias 4.
12. Subtract nonspecific binding (average of tubes 1,2) from the 5
average counts obtained from the 10 other tubes. Plot radioactivity in
cpm (y-axis) versus antibody dilution (x-axis).
Results and Discussion
There is sufficient apo B in LDL-coated IDE in the test tube assay for
mAB 3.01 and mAB T4 to bind when these mABs are diluted in the range
of 1:100 through 1:5000 as seen in Figure 6. For both mAB 3.01 and
mAB T4, a mAB dilution between 1:1000 and 1:5000, where the slope
remains constant, could be used to test stability of LDL apo B-1 00 coated
IDE particles.
Summary
We chose a dilution of 1:2000 for the mABs for subsequent studies
using a test tube assay.
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Legend for Figure 6
Optimization of a tube assay for LDL-coated IDE. CPM of 125l-labelled
whole IgG-mAB-apo B (bound to IDE) complex vs mAB dilutions. The
optimal mAB dilution is chosen from the part of the curve with a constant
slope, between 1:1000 and 1:5000.
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EXPERIMENT 5--EPIT0PE STABILITY STUDY
This experiment was designed to test the immunoreactivty of apo B
epitopes stabilized on IDE particles at 1,5, 12, 26 and 40 day intervals
after storage at -20C, 4C and 25 C. Coated and uncoated lyophilized
particles were included at the 26 day (14 days as lyophilized particles
stored at 4C), 40 day (28 days as lyophilized particles stored at 4C), 54
day (42 days as lyophilized particles stored at 4 C), and 68 day (56 days
as lyophilized particles stored at 4C) time intervals. Uncoated IDE
particles were tested simultaneously at the same time intervals and
storage temperatures. Coated IDE particles not exposed to mAB 3.01 or
T4, aliquoted at the same time as coated particles exposed to 3.01 and
T4, are used as nonspecific binding controls. The counts obtained from
the nonspecific binding controls are subtracted from the corresponding
coated particles which were exposed to mAB 3.01 or mAB T4.
MATERIALS AND METHODS
LDL (#321)-Coated IDE particles
The procedure for particle precipitation is the same as previously
described under Experiment 3, except 10 g of IDE are produced instead
of 5 g. Therefore, 192 mis IDE solution and 250 mis absolute ethanol are
combined initially, 500 mis 1% PVP (pH 5) are added during particle
precipitation, and 300 mis 1% PVP (pH 7.4) are added to stabilize the
particles. Just prior to coating particles, the batch is divided into two
equal portions and half of the batch is coated with 0.34 ml LDL (#321)
stock solution of 4.59 mg/ml to yield 2.5 pg LDL/ml IDE suspension. The
other half of the batch remains uncoated and serves as a control.
Particle suspension evaluation is the same as described under
Experiment 3.
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Lyophilization of IDE Particles
LDL-coated and uncoated IDE particles were divided into 1-ml
aliquots in 12x75 mm polystyrene test tubes, as for the samples tested at
-20C, 4C, and 25C. At STS (Sterilization Technical Services, Rush,
NY), the tubes were centrifuged at 2000 rpms (983xgmax) for 40 minutes
in an IEC PR2 centrifuge (International Equipment Corp., Boston, MA)
and the supernatant was removed. Incubation buffer and 20% sucrose
were combined to make a final concentration of 10% sucrose in the
concentration of incubation buffer as described in Materials and
Methods. One ml of this solution was added to each tube. The tubes
were frozen at -48C for 24 hours, then at -15C for the next 5 days,
under constant vacuum pressure to sublimate water present. Lyophilized
particles were stored at 4C until use.
mABs: 3.01 and T4
For the time-temperature study, each mAB was diluted 1:2000 with
incubation buffer. It was predetermined that 150 mis of each dilution (75
pis monoclonal antibody diluted with 150 mis incubation buffer) would be
required for the entire duration of the study. The mAB dilutions were
divided into 30 ml aliquots and stored at -20C until day of use.
Predilution of mAB was done to reduce variability of assay.
Second antibody: 125l-goat anti-mouse whole antibody
It was predetermined that 350 mis of second antibody would be required
for the entire time-temperature experiment (five assays). Therefore, 875
pis of ^l-goat anti-mouse whole IgG was diluted with 350 mis of
incubation buffer. This dilution was divided into 35 ml aliquots and
stored at -20C until needed. Predilution of antibody was done to reduce
variability of assay.
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Preparation of Particles for Epitope Stability Study
Five 50-ml centrifuge tubes containing uncoated particles and five
tubes containing LDL-coated particles were spun at 3400 rpm
(2260xgmax ) for 30 minutes at 4C in a Sorvall RT6000B Refrigerated
centrifuge, with about 12 mis particles in each tube diluted to 50 mis with
incubation buffer. For the second wash, about 10 mis buffer was added
to 2 mis particle pellets in each tube, vortexed and recentrifuged. After
the second wash, all five tubes of LDL-coated particles were combined
into one 50-ml tube and all five tubes of uncoated particles were
combined into another 50-ml tube. Incubation buffer was added to bring
the volume of each of these two tubes to 200 mis. The diluted particles
were aliquoted into prenumbered 12x75mm polystyrene test tubes.
Tubes devoted to each of 7 assays were numbered as follows.
TIMES: DAY1
LDL-coated IDE-
DAY 5 DAY 12 DAY 26 DAY 40
TEMP.
-20C 1-9 11-19 21-29 31-39 41-49
4C 51-59 61-69 71-79 81-89 91-99
25C 101-109 111-119 121-129 131-139 141-149
Lyophile 151-159 161-169







DAY 12 DAY 26 DAY40
TEMP.
-20C B1-6 B7-12 B13-18 B19-24 B25-30
4C B31-36 B37-42 B43-48 B49-54 B55-60
25C B61-66 B67-72 B73-78 B79-84 B85-90
Lyophile B91-96 B97-102
DAY 54 DAY 68
Lyophile B103-109 B110-116
Procedure for Epitope Stability Study
1 . Particles for one assay are equilibrated at 25C for 2 hours.
2. Particles are spun at 2800 rpm (1533xgmax) for 10 minutes at 25C.
The supernatant is discarded.
3. Particles are resuspended in primary antibody (mAB 3.01 or T4) or
antibody buffer alone as follows and incubated overnight (22 hours)
at 4C:
mAB 3.01 mABT4 Incubation buffer
TEMP.
-20C 1-3 4-6 7-9 LDL-Coated IDE
B1-3 B4-6 Uncoated IDE
4C 51-53 54-56 57-59 LDL-Coated IDE
B31-33 B34-36 Uncoated IDE
25C 101-103 104-106 LDL-coated IDE
B61-63 B64-66 Uncoated IDE
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Lyophile (included in 4th-7th assays); for 4th assay:
151-153 154-156 157-159 LDL-Coated IDE
B91-93 B94-96 Uncoated IDE
4. Centrifuge tubes at 2800 rpm (1533xgmax) for 10 minutes at 25C.
Discard the supernatant. All tubes are washed 3 times in 1 ml
incubation buffer.
5. After supernatant is removed following the last wash, add 1 ml 125l-
labelled second antibody to each tube, vortex to mix, and incubate for
22 hours at 4C.
FOR A DECAY PLOT OF ^l SECOND ANTIBODY:
Add only 0.1 ml 125l second antibody to each of 6 tubes. Store these
tubes at 4C until ready for counting.
6. Centrifuge tubes at 2800 rpm (1533xgmax)) for 10 minutes at 25C.
Discard supernatant. Wash 3 times with 1 ml incubation buffer in
each tube for each wash.
7. After supernatant discarded following the last wash, add 0.1 ml
incubation buffer to each tube and vortex to resuspend particles.
8. Count tubes on Packard Multi-Prias 4 gamma counter for 10 minutes
each.
9. Subtract counts for tubes not incubated with primary monoclonal
antibody from tubes incubated with primary monoclonal antibody 3.01
and T4 to correct for nonspecific binding.
10.To correct for radioactive decay, calculate radioactivity back to day
zero for 125l-goat anti-mouse whole antibody counts for each assay
using the decay chart (22) in Table 2.
1 1 . Control experiments to test IDE particle settling on radioassay of 125l
a) Determine if there is short-range settling by vortexing 12 tubes
(with >50,000 cpm to insure less than 1% counting error) once
and loading a rack to be counted for 10 minutes each over 6
consecutive times, for a total range of 180 minutes. Each tube is
counted for 10 minutes on the Packard Multi-Prias 4 gamma
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counter. Count corrections are made for radioactive decay
of the
isotope using the decay chart (Table 2).
b) Determine if there is long-range settling by vortexing
19 tubes
(with >30,000 cpm to insure less than 1% counting error)
once for
30 seconds each and counting these tubes
for 10 minutes each on
the Packard Multi-Prias 4 at 1.25 hours, 5.5 hours and 22.75
hours
after vortexing. Radioactive decay of the isotope is corrected for
using the decay chart (Table 2).
For the short term settling test, the counts obtained
180 minutes after
vortexing were divided by counts obtained immediately
after vortexing.
The values for corresponding tubes (last run/initial run) are
averaged to
obtain a percentage rate of particle settling for the last run (180 minutes
after vortexing).
For the long range settling test, 1.25 hours after vortexing was
considered the initial run, 5.5 hours the next, and 22.75 hours after
vortexing the last run. The values obtained from the second run (5.5 hrs)
were divided by the initial run (1.25 hrs). The counts for the last run
(22.75 hrs) were also divided by the counts for the initial run (1.25 hrs).
Percentage differences between runs were calculated by averaging the
values obtained from these comparisons. Linear regression is used to
determine particle settling for times other than those tested. Data
obtained from the Epitope Stability Study are corrected for settling based
on particle settling experiments. Dr. James Corsetti from the Clinical
Chemistry at the University of Rochester kindly provided a computer
program based on linear regression and the decay chart to correct for
particle settling and radioactive decay of the 125l-goat anti-mouse whole
IgG.
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Table 2. 125l Decay chart for Epitope Stability Study.
From New England Nuclear product insert (22), used to correct
for radioactive decay throughout the epitope stability study.Note
that the half-life of 125l is 60 days.
DAYS
DAYS 0 2 4 6 8 10
0 1.00 .977 .955 .933 .912 .891
20 .794 .776 .758 .741 .724 .707
40 .630 .616 .602 .588 .574 .561 .548 .536 .524 .512
60 .500 .489 .477 .467 .456 .445 .435 .425 .416 .406
80 .397 .388 .379 .370 .362 .354 .345 .338 .330 .322
12 14 16 18
.871 .851 .831 .812
.691 .675 .660 .645
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RESULTS AND DISCUSSION
Characterization of IDE and LDL-coated IDE particles
For IDE preparation, precipitation occured at +0.5C and
after
approximately 230 mis were infused. When the Infusion
was complete,
temperature was 7C. Temperature after stabilization was 1C. For
Crystal and Aggregate test after particle stabilization, adjust to 3 mg
IDE/ml using: 10,493 mg IDE/1242 ml
= 8.4 mg IDE/ml x 36 pl/100 pi.
Therefore, 36 pi IDE particle suspension is diluted with 64 pi 0.1% PVP
(pH 7.4). For Crystal and Aggregate test after washing IDE, use XES
value for final density value. Dilute final concentration of 47 mg IDE/ml x
32 pl/500pl to = 3 mg IDE/ml.
Crystal and Aggregate test after stabilization of IDE batch
PJD 32-71 Size: >25p >10p >5p >1p
Aggregate: max# allowed:
PJD 32-71 # counted: 0 0 0 0 Passes
Crystal: max # allowed:
PJD 32-71 # counted: 0 0 0 1 Passes
<1 <2 <7 <27
<1 <2 <5 <15
test before LDL addition for
Size: >25p >10p >5p >1^
<1 <2 <7 <27
0 0 0 0
<1 <2 <5 <15
1 2 3 3
PJD 32-71 a
Aggregate: max # allowed:
PJD 32-71 a # counted: Passes
Crystal: max # allowed:
PJD 32-71 a # counted: 2 Passes
Crystal and Aggregate test after addition of LDL for batch
PJD 32-71 b Size: >25p >10p <5p >1p
Aggregate: max# allowed: <1 <2 <j <2j
PJD 32-71 b# counted: 0 0 0 0 Passes
Crystal: max # allowed: <1 <2 <5 <15
PJD 32-71 b# counted: 1 2 5 15 Passes
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Diameter determinations before LDL addition & After LDL
addition
N4 Analysis: Unimodal Mean SD Mean SD
32-71.1 255 57 263 57
.2 257 56 270 61
.3 257 56 263 59
.4 258 50 266 Narrow
AVG 257 55 266 59
Density determination
XES: Integrate I divided by 0.637 = IDE x
321-364 mg/ml mg/ml
STD 80 92,891 78.1
STD 10 38,874 9.5
PJD 32-71 a (Control):
volume= IDE
ml ml
56,441 28.7 45.1 50 2255
56,954 29.3 46.0 50 2302
56,872 29.2 45.9 50 2294
AVG 45.7 50 2284
PJD 32-71 b (LDL-coated):
57.468 29.9 47.0 50 2349
57,953 30.5 47.9 50 2395
57,622 30.1 47.3 50 2364
AVG 47.4 50 2369
(1) For 80 STD, calculate I using
y= 0.004994x-squared + 0.6098 - 21.60;
R=0.9996
(2) For 10 STD, calculate I using y
= 0.8813 x(-24.74); R=0.9992
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Recovery: In: 10,493 mg IDE
Out: 2284 mg IDE Control
(Uncoated IDE) = 43.5% recovery
2369 mg IDE LDL-Coated
IDE = 45.2% recovery
A plot of relative percent of cpm of the radiolabeled
125l-goat anti-
mouse whole IgG (y-axis) versus days (x-axis)
illustrates experimental
decay of 125l and its half-life, as seen in Figure
7.
For the 3-hour short-range settling check done
when the isotope was
32 days old, the decay factor changes by 0.008 (0.691-0.683)
within 24
hours. The hourly rate of change is 0.008/24=0.00033.
The decay correction factor for the sixth and
last count is
0.00033x1.83 hours=0.00061, which is multiplied by each count
obtained in the last run. Only the first and and last runs are compared.
An average percentage rate of change in counts due to particle settling is
determined to be 1%.
For the long-range settling test done when the isotope was 60 and 61
days old, the decay factor changes by 0.0055 (0.500-0.495) within 24
hours. The hourly rate of change is 0.000229 (0.0055/24 hours). For the
difference between 1.25 and 5.5 hours, the correction factor is 0.00097
(0.00029x4.25 hours). Counts for 5.5. hours are multiplied by this factor.
An average of 1% decrease in counts is determined. For the comparison
of 1.25 and 22.75 hours after vortexing, the correction factor is 0.0052
(0.00029x22.75 hours). There is a 6% decrease in counts between the
initial and last runs.
Refer to Figures 8a and b for plots of particle-bound apo B as a
function of time for mAB 3.01 and mAB T4 at -20C, 4C and 25C. Forty
days after storage at -20C, 4C and 25C, IDE-stabilized LDL (apo B-
100) epitopes are still reactive with both mAB 3.01 and mAB T4. For apo
B epitope detection by mAB 3.01, there is still approximately 80%
immunoreactivity when LDL (apo B-100)-coated IDE are stored at -20C
and 4C, and about 72% when stored at 25 C for 40 days.
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Legend for Figure 7
For a decay plot of 125l second antibody, 0.1 ml 125l second antibody was
added to each of 6 tubes for all seven assays. The counts obtained for
each were averaged and plotted as a relative % of the highest CPM
value. A logarithmic curve fit was applied. The 125l half-life (50% on y-
axis) may be determined from the corresponding value on the x-axis.
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Figure 8a. Apo B immunoreactivity over time,




























Legend for Figure 8a
Plot of immunoreactivity of IDE-bound apo B with mAB 3.01 as a function
of time at -20C, 4C and 25C.
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Figure 8b. Apo B immunoreactivity over time,

































Legend for Figure 8b
Plot of immunoreactivity of IDE-bound apo B with mAB T4 as a function of
time at -20C, 4C and 25C.
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For apo B epitope activity with mAB T4, immunoreactivity at 40 days is
still about 80% for apo B on IDE stored at -20C, approximately 72%
when stored at 4C and 60% when stored at 25C. Table 3 lists relative
percent immunoreactivity of apo B epitopes as determined from plots of
relative counts vs time (days). Control (uncoated IDE) cpm were usually
around 10% of the cpm for LDL-coated IDE for both mABs. A first order
decay process was used to model the decline of apo B immunoreactivity
over time at each temperature and the resultant decay constants were
used to determine the respective half-lives (half-life=ln2/k). Half-life
values decrease with increasing storage temperature for both mABs
used (Figures 9 and 10). A plot of counts for the T4 vs 3.01 assays for all
the time points at each temperature is given in Figure 1 1. It demonstrates
excellent linear correlation between the results of the two assays.
Figure 12 contains Arrhenius plots for both mABs 3.01 and T4. The y-
axis value is the natural log of the rate constant k and is plotted against
the reciprocal of the absolute temperature value at which the apo B was
stored. The activation energy is determined from the slope of the
Arrhenius plot, where slope=E/R and R is 1.987 cal/K-mole. For apo B
epitope detection by mAB 3.01, E=2.10 kcal/mole. For apo B epitope
detection by mAB T4, E=2.7 kcal/mole. The relatively small activation
energies suggest only slight temperature dependence of the loss of apo
B-1 00 immunoreactivity over time.
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Table 3. Relative % immunoreactivity of apo B epitopes as
determined from relative counts vs time (days) plots in
Figures 8a and 8b.
STORAGE TIMES: 1d 5d 12d 26d 40d
mAB 3.01
TEMPERATURE
-20C 100 85 85 85 80
4C 100 95 95 93 80
25C 100 95 93 85 72
mABT4-
TEMPERATURE
-20C 100 95 100 92 80
4C 100 88 90 90 72
25C 100 88 86 75 60
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Figure 9a. Half-life for apo B





















Legend for Figure 9a
Plot of relative counts of immunoreactivity of IDE-bound apo B with mAB
3.01 as a function of number of years IDE-bound apo B stored at -20C.
The data was used to determine the best fit exponential decay equation
and the resultant first order decay constant (k) was used to calculate half-
life of IDE-bound apo B epitopes stored at -20C (half-life=ln2/k).
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Legend for Figure 9b
Plot of relative counts of immunoreactivity of IDE-bound apo B with mAB
3.01 as a function of number of years IDE-bound apo B stored at 4C.
The data was used to determine the best fit exponential decay equation
and the resultant first order decay constant (k) was used to calculate half-
life of IDE-bound apo B epitopes stored at 4C (half-life=ln2/k).
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Legend for Figure 9c
Plot of relative counts of immunoreactivity of IDE-bound apo B with mAB
3.01 as a function of number of years IDE-bound apo B stored at 25C.
The data was used to determine the best fit exponential decay equation
and the resultant first order decay constant (k) was used to calculate half-
life of IDE-bound apo B epitopes stored at 25C (half-life=ln2/k).
68





















0.055 0.082 0.110 0.137
Time (years)
69
Legend for Figure 10a
Plot of relative counts of immunoreactivity of IDE-bound apo B with mAB
T4 as a function of number of years IDE-bound apo B stored at -20C.
The data was used to determine the best fit exponential decay equation
and the resultant first order decay constant (k) was used to calculate half-
life of IDE-bound apo B epitopes stored at -20C (half-life=ln2/k).
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Legend for Figure 10b
Plot of relative counts of immunoreactivity of IDE-bound apo B with mAB
T4 as a function of number of years IDE-bound apo B stored at 4C. The
data was used to determine the best fit exponential decay equation and
the resultant first order decay constant (k) was used to calculate half-life
of IDE-bound apo B epitopes stored at 4C (half-life=ln2/k).
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Legend for Figure 10c
Plot of relative counts of immunoreactivity of IDE-bound apo B with mAB
T4 as a function of number of years IDE-bound apo B stored at 25C.
The data was used to determine the best fit exponential decay equation
and the resultant first order decay constant (k) was used to calculate half-
life of IDE-bound apo B epitopes stored at 25C (half-life=ln2/k).
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Legend for Figure 1 1
Scatter plot of counts for detection of IDE-bound apoB immunoreactivity
by mAB T4 vs mAB 3.01. This illustrates linear correlation for the two
mABs detecting IDE-bound apo B after it is stored at -20C, 4C and
25C.
76



















y = -1 057.605X
- 1 .379 r = 0.957 ^^^n
\ i i




Legend for Figure 12a
The Arrhenius plot is based on k=Ae-E/RT, or In k=ln A - E/RT, where
R=1 .987 cal/K-mole). This is a graph of the natural log of the decay
constant vs the reciprocal of the absolute temperature (1/K) of the
storage temperature for IDE-bound apo B prior to the assay. E is
determined from the slope of the curve, -E/R. The calculated E=2.1
kcal/mole indicates that apo B immunoreactivity (detected by mAB 3.01)
is only slightly temperature-dependent.
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Legend for Figure 12b
The Arrhenius plot is based on k=Ae-E/RT, In k=ln A - E/RT, where R=1.987
cal/K-mole). This is a graph of the natural log of the decay constant vs
the reciprocal of the absolute temperature (1/K) of the storage
temperature for IDE-bound apo B prior to the assay. E is determined
from the slope of the curve, -E/R. The calculated E=2.7 kcal/mole
indicates that apo B immunoreactivity (detected by mAB T4) is only
slightly temperature-dependent.
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IDE-stabilized LDL (apo B-1 00) counts are very decreased after the
28-day assay for the lyophilized particles (14 days in lyophilized state)
stored at 4C, as observed from the graph in Figure 13. Apo B epitopes
detected by mAB 3.01 change from 95% relative immunoreactivity after
28 days as lyophile to 48% after 42 days as lyophile (Table 4). As for the
nonlyophilized IDE, reconstituted lyophilized control (uncoated IDE) cpm
were approximately 10% of the cpm for reconstituted lyophilized
LDL-
coated IDE for both mABs. The New England Nuclear product insert for
the 125l-labelled whole IgG states that the product shoud be stored at
-20C or lower to remain stable for at least 4 weeks. The product was
stored at 4C after the dilutions were made and frozen at -20C for the
first five assays. When the study was extended to include testing
lyophilized LDL-coated and uncoated IDE, a new dilution of the
radiolabeled polyclonal antibody was prepared, after it had been stored
at 4C for 55 days.
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Legend for Figure 13
Plot of relative counts of immunoreactivity of reconstituted lyophilized
IDE-bound apo B detected by mABs 3.01 and T4. as a function of number
of days as lyophile.
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Table 4. Relative % immunoreactivity of apo B epitopes as
determined from relative counts vs time (days) plot in
Figure 13 for reconstituted lyophilized LDL-coated IDE.
Age of LDL (apo B) 41d 55d 79d 83d
Time as lyophile 14d 28d 42d 56d
mAB 3.01 100 95 48 48
mABT4 100 95 45 42
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Some observations about the difficulty in resuspending IDE pellets after
centrifugation follow. After 28 days as lyophile, reconstituted lyophilized
particles were consistently difficult to resuspend. Small visible clumps
(<1 mm) of IDE particles remained in all tubes even after 5 minutes of
vortexing, while before the 26-day assay (lyophile for 14 days), 1 minute
was usually sufficient time to resuspend particles. After storage as
lyophile for 42 days, one tube retained a medium-sized pellet (3-5 mm)
after 5 minutes of vortexing. After storage for 56 days as lyophile, 3 tubes
still had medium-sized pellets after 5 minutes of vortexing. Prior to 28
days as lyophilized IDE, particles in 6 tubes at the 26 day (14 days as
lyophile) were difficult to resuspend in 1 ml primary antibody after
centrifugation. After addition of 1 ml primary antibody, one of these tubes
required 10 minutes to resuspend and the other 5 needed 5 minutes. For
most tubes containing nonlyophilized IDE particles, it took 30-60 seconds
for resuspension of particles. Occasionally, there was difficulty with
resuspending particles from the pellet during the 1, 5, 12, 26 and 40 day
assays for particles stored at -20, 4 and 25C. After 15 minutes of
vortexing, pellets from two tubes stored at 25 C for 5 days did not
completely resuspend after the radiolabeled antibody was added. After
the second wash step to remove this antibody, one of these two tubes
required 10 minutes and the other tube 15 minutes of vortexing to
completely break up the pellet. At the 12 day timepoint, one tube stored
at -20C was vortexed for 12 minutes after primary antibody as added,
but still had visible clumps (<1 mm). It also needed about 5 minutes to
resuspend in buffer during the wash steps. At the 40 day assay, two
tubes stored at 4 C were vortexed about 8 minutes and one tube stored
at -20 C was vortexed about 15 minutes to resuspend the particles in 1
ml buffer after centrifugation.
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SUMMARY
Work done to characterize apo B has demonstrated that this very
large protein may be altered by mechanical shear, proteolysis,
oxidation
and self-aggregation after delipidation of the natural LDL core. The
epitope stability study tests the immunoreactivity of
apo B epitopes using
two mABs.
Preliminary work included a comparison of three
modifications of
Immulon plastic microtiter wells to determine which plastic binds human
apo B most effectively and to establish a workable standard
curve for
human LDL. There was little difference among the three plastics.
Therefore, it was decided to continue using Immulon 2 microtiter wells,
currently in use at the laboratory. The goal of the second experiment was
to establish a standard curve for LDL-coated IDE. As there was not
sufficient apo B bound to the IDE particles in this experiment, the
decision was made to switch to a test tube assay. The purpose of the test
tube assay was simplified to establish the optimal mAB dilutions to use
for the epitope stability study, rather than to determine a workable
standard curve for LDL-coated IDE particles. A 1:2000 dilution of mAB
was selected from the part of the curve with a constant slope for both
mAB 3.01 and T4.
The epitope stability study tested LDL-coated IDE particles at -20C,
4C and 25C. Reconstituted lyophilized IDE particles, LDL-coated and
uncoated, were also tested. Intact apo B epitopes react with mAB 3.01
(carboxy terminal specific) or mAB T4 (amino terminal specific). It was
determined that LDL-coated IDE stored for 40 days at -20C and 4C
retain 80% immunoreactive epitopes when detected with mAB 3.01.
There is 72% reactivity for the 25C data. LDL-coated IDE retains 80%
epitope reactivity when detected by mAB T4 for 40 days at -20C. When
the storage temperature is 4C, about 72% of the apo B-1 00 epitopes
remain immunoreactive, relative to the first assay for reconstituted
lyophilized LDL-coated IDE. At 25C, about 60% of the apo B epitopes
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retain immunoreactivity. Lower storage temperatures favor longer apo B-
100 epitope stability and appear to be effective in slowing the
process(es) leading to degradation of apo B epitopes defined by these
mABs.
After 28 days stored as lyophilized 1-ml aliquots in plastic-stoppered
polystyrene tubes at 4C, reconstituted lyophilized IDE results in
approximately 95% stable apo B antigenic sites (Figure 13). After 42
days as lyophile, apo B has only 45-48% reactivity. Perhaps storing the
lyophilized particles under vacuum or dessicated conditions would
lengthen the shelf life of these particles.
The radiolabeled polyclonal antibody was stored for 55 days at 4C
before it was diluted for the last two assays for the reconstituted
lyophilized particles, yet it was assumed to remain stable throughout the
study. Testing the stability of the monoclonal and polyclonal antibodies
could prove useful in the interpretation of the data collected in the
epitope stability study.
Since there was some difficulty in resuspending IDE pellets after
centrifugation or reconstitution of lyophilized particles, perhaps adding
0.1% of the surfactant PVP (pH 7.4) to the incubation/wash/dilution buffer
used in the assay could help to correct this problem in any future epitope
stability studies utilizing IDE.
The interpretation of the study of immunoreactivity of LDL-coated IDE
and reconstituted lyophilized LDL-coated IDE is complicated by the fact
that the LDL used in this study was 13 days old when coated onto IDE
particles. Until the coating process, the LDL was stored at 4C
with 2.5
mM EDTA. Lyophilization of part of the batch of LDL-coated and
uncoated IDE did not occur until the LDL was 27 days old (Table 5).
lyophilized particles. Therefore, the conclusions for this study are based
upon LDL which had most likely started to undergo degradation before it
was coated onto IDE particles and lyophilized.
Results would be
expected to reflect a slightly more prolonged rate
of degradation of apo B
epitopes had the LDL been fresher when IDE coating and lyophilization
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took place. Considering that it takes 2 days for LDL separation and
protein determination, 2 days for IDE precipitating/coating/quality control
and 6 days for the lyophilization procedure, the minimum age of LDL at
the start of an apo B epitope stability study could be 10 days.
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Table 5. Comparison of storage time before assay vs
Total age of LDL in vitro vs
Length of time LDL coated onto IDE vs
Length of time LDL-coated IDE stored as lyophile
before assayed in Epitope Stability Study
Incubation time --> 1d 5d 12d 26d 40d 54d 68d
Age of LDL > 16d 20d 27d 41 d 55d 79d 83d
LDL on IDE > 3d 7d 14d 28d 42d 56d 70d
Lyophilized LDL -> 14d 28d 42d 56d
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